Current Report Filing (8-k)
13 May 2022 - 06:11AM
Edgar (US Regulatory)
false000146944300014694432022-05-122022-05-12
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of
1934
|
|
Date of Report (Date of earliest event reported):
May 12, 2022
|
Arcadia Biosciences, Inc.
(Exact name of Registrant as Specified in Its Charter)
|
|
|
|
|
|
Delaware
|
001-37383
|
81-0571538
|
|
(State or Other Jurisdiction
of Incorporation)
|
(Commission File Number)
|
(IRS Employer
Identification No.)
|
|
|
|
|
|
|
|
202 Cousteau Place
Suite 105
|
|
|
Davis,
California
|
|
95618
|
|
(Address of Principal Executive Offices)
|
|
(Zip Code)
|
|
|
Registrant’s Telephone Number, Including Area Code:
530
756-7077
|
(Former Name or Former Address, if Changed Since Last
Report)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
☐Written
communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425)
☐Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
☐Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR 240.14d-2(b))
☐Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the
Act:
|
|
|
|
|
|
Title of each class
|
|
Trading
Symbol(s)
|
|
Name of each exchange on which registered
|
|
Common
|
|
RKDA
|
|
The NASDAQ Stock Market LLC
|
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933
(§ 230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange
Act. ☐
Item 2.02 Results of Operations and Financial Condition.
On May 12, 2022, Arcadia Biosciences, Inc. (the “Company”) issued a
press release announcing financial results for the first quarter
ended March 31, 2022. A copy of the press release is furnished as
Exhibit 99.1, and the Company's annual financial information tables
are furnished as Exhibit 99.2, to this Current Report on Form 8-K
and are incorporated herein by reference.
The information furnished in this Form 8-K, the press release
attached as Exhibit 99.1, and the financial information attached as
Exhibit 99.2, shall not be deemed “filed” for purposes of Section
18 of the Securities Exchange Act of 1934, as amended, or otherwise
subject to the liabilities of that section or Sections 11 and
12(a)(2) of the Securities Act of 1933, as amended. The information
contained in this Item 2.02, in the press release attached as
Exhibit 99.1, and in the financial information attached as Exhibit
99.2, shall not be incorporated by reference into any filing with
the U.S. Securities and Exchange Commission made by the Company,
whether made before or after the date hereof, regardless of any
general incorporation language in such filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on
its behalf by the undersigned thereunto duly authorized.
|
|
|
|
|
|
|
|
ARCADIA BIOSCIENCES, INC.
|
|
|
|
|
|
|
Date:
|
May 12, 2022
|
By:
|
/s/ PAMELA HALEY
|
|
|
|
|
Pamela Haley, Chief Financial Officer
|
Arcadia Biosciences (NASDAQ:RKDA)
Historical Stock Chart
From May 2022 to Jun 2022
Arcadia Biosciences (NASDAQ:RKDA)
Historical Stock Chart
From Jun 2021 to Jun 2022
